Die postmenopausale osteoporose aus gynäkologischer sicht

Gynakologe

Volumn 29, Issue 9, 1996, Pages 735-741

  Doren M ^a,b   Schneider, H E G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; COLECALCIFEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; NORGESTREL; VITAMIN D;

BONE MASS; FRACTURE; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TRANSDERMAL DRUG ADMINISTRATION;

EID: 3242836226     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001290050072     Document Type: Article

References (31)

1. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327: 1637-1642
2. Christiansen C, Riis BJ (1990) 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endo Metab 71: 836-841
3. Consensus Development Conference (1991) Prophylaxis and treatment of osteoporosis. Am J Med 90: 107-10
4. Consensus Development Conference (1996) Who are candidates for prevention and therapeutic therapy for osteoporosis? Amsterdam, Mai 1996
5. Dören M, Reuther G, Minne HW, Schneider HPG (1995) Superior compliance and efficacy of continuous combined oral estrogen and progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 73: 1446-1451
6. Felson DT, Zhang Y, Hannan M, et al. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329: 1141-1146
7. Gallagher JC, Riggs BL, Recker RR, Goldgar D (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191: 287-292
8. Hillard TC, Whitcroft SJ, Marsh MS (1994) Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 4: 34-38
9. Johnston CC, Melton LJ, Lindsay R, Eddy DM (1989) Clinical indications for bone mass measurements. Report of Scientific Advisory Committee of the National osteoporosis Foundation. J Bone Min Res 4 [Suppl 2]: 1-28
10. Kanis JA, Johnell O, Gullberg B et al. (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305: 1124-1128
11. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA (1987) Hip fracture and the use of estrogen in postmenopausal women: The Framingham study. New Engl J Med 317: 1169-1174
12. Lafferty FW, Fiske ME (1994) Postmenopausal estrogen replacement: A long-term cohort study. Am J Med 97: 66-77
13. Lindsay R, Aitken JM, Anderson JB, Hart MD, MacDonald EB, Clark AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1: 1038-1041
14. Lindsay R, Hart DM, Clarke DM (1984) The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63: 759-763
15. Lindsay R, Tohme JF (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295
16. Lufkin EG, Wahner HW, O'Fallon WM et al. (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 117: 1-9
17. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) How many women have osteoporosis? Bone Miner Res 7: 1005-1010
18. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM (1979) Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 53: 277-281
19. Nielsen SP, Bärenholdt O, Hermansen F, Munk-Jensen N (1994) Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol 101: 319-324
20. 3. Bone Min 3: 47-52
21. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salmon calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305: 556-561
22. Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ (1990) Treatment of high remodeling vertebral osteoporosis with human calcitonin: A two-year double-blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress, Kopenhagen, pp 1430-1432
23. Pientka L, Grüger L (1996) Die ökonomische Bedeutung der Osteoporose in Deutschland. Der Kassenarzt 8: 44-52
24. Reginster JY (1993) Osteoporsis: overview of different therapies. In: Christiansen C, Riis B, (eds) Osteoporosis, Proceedings 1993 of the Fourth International Symposium on Osteoporosis, Handelstrykkeriet Aalborg ApS, Aalborg, pp 354-356
25. Riggs BL, Hodgson SF, O'Fallon WM et al. (1990) Effect of fluoride treatment on the fracture rate inpostmenopausal women with osteoporosis. N Engl J Med 322: 802-809
26. Riggs BL, Sccman E, Hodgson SF, Taves DR. O'Fallon WM (1982) Effects of the fluoride/calcium regimen on vertebral fracture occurence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 306: 446-450
27. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265-1271
28. Tilyard MW (1990) Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism 39 [Suppl 1] 1: 50-52
29. Watts NB, Harris ST, Genant HK et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73-79
30. Wimalawansa SJ (1995) Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four year randomized study. Am J Med 99: 36-42
31. WHO Technical Report Series 843 (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group, WHO. Genf. 1994